PubMed Health⌕ Search

Biomedical subjects

I Taki

Publications and source records attributed to I Taki.

At least 19 recordsLinked to original sources
PubMed1996

An external reference for in vivo quantification of 1H spectroscopy.

We studied the validity of using an external signal reference for absolute quantification of brain metabolites. We chose cyclohexane as the signal standard. An expression of a perturbed magnetic field in diamagnetic cylindrical materials was first obtained by using a method of equivalent magnetic charges. Broadening of the spectrum in this perturbed magnetic field was then computed. We performed phantom studies. We measured the full width at half maximum (FWHM) of the cyclohexane and the signal ratio (SR) between water and cyclohexane in spheres of two different diameters, and in cylinders of various diameters and lengths. The observed FWHM and SR in the small cylinders had large variations in distribution, whereas those in the spheres and in the large cylinders had small variations. Specifically, in a cylinder with a diameter > 5 cm and with a length > 10 cm, the variation of the SR was < 1.0%. The diameter and the length of the cylinder preferably are large when a cylindrical material is adopted as an external signal standard.

Brain↗
PubMed1996

[Quantification of brain metabolites by 1H spectroscopy using cyclohexane as an external reference].

We tested the reliability of quantifying brain metabolite concentrations by MR spectroscopy. We employed a PRESS sequence and used a cyclohexane sample as an external standard. The signal intensity ratios of water and cyclohexane were measured by changing the geometrical arrangement of the cyclohexane sample and water phantom with various loading factors of the coil. Choline (Cho) concentrations were calculated from the signal intensity ratios of Cho and water and compared with actual Cho concentrations (1.0 to 2.6 mmol/L). The brain metabolites Cho, creatine/phosphocreatine (Cr/PCr) and N-acetylaspartate (NAA) were evaluated in five normal volunteers and six patients with metastatic brain cancer before (0 Gy), after 20 Gy and after 40 Gy of whole brain radiotherapy. Variation in the ratio of spectrum intensity between water and cyclohexane was less than 1.5% for various geometrical arrangements and loading factors. The error in quantification of Cho concentrations in the phantom study was 0.05 +/- 0.10 mmol/L. The concentrations measured in the volunteers were: Cho 1.6 +/- 0.4 mmol/L, Cr/PCr 6.4 +/- 1.1 mmol/L and NAA 8.2 +/- 0.1 mmol/L. There was no significant difference (p > 0.05) in these concentrations between the control group and the patients before, during, or after radiotherapy.

Adult↗
PubMed1990

Comparative study of combination chemotherapy of ovarian cancer: cyclophosphamide, adriamycin and cisplatin versus 5-fluorouracil, cyclophosphamide and mitomycin C.

CAP, a multiple-drug combination therapy using cyclophosphamide (750 mg/m2), adriamycin (20-30 mg/m2) and cisplatin (50-75 mg/m2), was applied to 69 cases of epithelial ovarian cancer. The results of this therapy were compared with those of FAM (involving 5-fluorouracil, cyclophosphamide and mitomycin C) in 47 cases of the same cancer, retrospectively. The 5-year survival rate was 61.6% for cases treated with CAP and 56.3% for cases treated with FAM. All 9 patients at stage Ia treated with CAP are free of disease, however, 3 patients out of 13 at stage Ia treated with FAM experienced a recurrence of the disease and died. In stage III and IV cases with detectable lesions, a response was observed in 61.3% (19/31) treated with CAP and in 10.5% (2/19) treated with FAM.

Adolescent↗
PubMed1987

[Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].

The chemotherapeutic effects of cisplatin + adriamycin + cyclophosphamide (PAC) on 50 epithelial ovarian cancers were compared with the effects of 5-fluorouracil + cyclophosphamide + mitomycin C (FAM) in 17 patients. The cumulative survival at 5 years was 61.1% in all patients, 62.5% in patients treated with PAC and 54.7% in patients treated with FAM. The 5-year survival rate was 100% in Stage I, 63.5% in Stage II, 40.1% in Stage III and 22.2% in Stage IV. Of 22 patients with Stage III and IV treated with PAC, 16 patients responded (8CRs + 8PRs). The median survival duration of the treated patients was 19 months. On the other hand, of 8 patients treated with FAM, only one patient responded (PR). The median survival duration was 7 months. These results indicated the effectiveness of PAC chemotherapy against advanced ovarian cancer. No severe toxicity was observed during treatment with PAC or FAM.

Adolescent↗
PubMed1984

Verrucous carcinoma of the uterine cervix: report of a case with follow-up of 6 1/2 years.

A case of verrucous carcinoma of the uterine cervix was reported with a long-term follow-up and close observation. The patient was a 73-year-old, Japanese female, who had a suspicious Papanicolaou smear on routine examination. The cervix was replaced by a papillary mass, which was diagnosed as benign papilloma. The patient was followed every 6 months with cytology, colposcopy, and punch biopsy. No cytologic or microscopic diagnosis of invasive squamous cell carcinoma was made during the entire follow-up period. Total abdominal hysterectomy and partial vaginectomy were performed after 6 1/2 years' follow-up, and the tumor was finally diagnosed as verrucous carcinoma. The patient is alive and well 4 years after the operation.

Adult↗
PubMed1982

Abortifacient effect and uterine cervix-dilating action of 16, 16-dimethyl trans delta 2 PGE1 methyl ester (ONO 802) in the form of a vaginal suppository (a randomized, double-blind, controlled study in the second trimester of pregnancy).

A newly synthesized 16, 16-dimethyl trans delta 2 PGE1 methyl ester (ONO 802) was clinically applied in the form of a vaginal suppository for therapeutic abortion of second trimester pregnancies. Its effects were studied in a double-blind test comparing it with an inactive placebo suppository. The study was conducted at 12 Japanese university hospitals. The number of patients was 125 in total, i.e. 63 receiving ONO 802 vaginal suppository (containing 1.0 mg ONO 802) and 62 receiving inactive placebo suppository. ONO 802 was more effective than placebo with a success rate of 87% (complete (71%) and incomplete (16%) abortions). The onset of uterine contractions was observed in 154.3+/-18.1 min. and the onset of uterine bleeding in 323.6+/-41.0 min. The expulsion of the fetus and placenta was observed in 955.4+/-97.0 and 961.6+/-97.0 min., respectively. The cervix dilating effect of ONO 802 was observed in 63.5% of the patients at 3 hours after the start of administration. Nausea, vomiting, abdominal cramps, diarrhea and pyrexia were noticed. However, all these side effects were transient and mild, requiring no treatment. No abnormality was observed in the puerperal course, duration of uterine bleeding or onset of subsequent menstruation following the therapeutic abortion. Therefore, the present study demonstrated that ONO 802 vaginal suppository was an effective and valuable drug for therapeutic abortion of second trimester pregnancies.

Abortifacient Agents↗
PubMed1982

Teratoma of the neck in a newborn infant--a case report.

A case of teratoma of the neck in a newborn is presented. Teratoma of the neck is a rare lesion and is mostly found in the newborn, but in some cases in the fetus and stillborn infant. Although in this case prenatal diagnosis was possible via ultrasonography, the infant did not survive because of respiratory distress. Hence, urgent surgery is imperative in such cases.

Head and Neck Neoplasms↗
PubMed1981

Teratoma of the neck in a newborn infant - a case report.

A case of teratoma of the neck in a newborn baby is presented. Teratoma of the neck is a rare lesion and almost always found in the newborn, but also in the fetus and stillborn infant. Although the mass was found prenatally by ultrasonography in the present case, the patient could not be saved because of respiratory distress. Urgent surgical management is the only way to save life in this kind of neonate.

Female↗
PubMed1981

[Cryosurgery for dysplasia, carcinoma in situ, and microinvasive carcinoma of the uterine cervix (author's transl)].

One hundred and three patients with dysplasia, carcinoma in situ, or microinvasive carcinoma of the uterine cervix were treated with cryosurgery during 8 years from 1972 to 1978. Twenty-nine patients underwent several types of operations during 4-41 days (mean 18 days) after cryosurgery, and 74 patients were followed for 3-78 months (mean 3 years) after treatment. Seventy-six per cent of the patients who underwent an operation had residual lesions in their histologic materials. Seventy per cent of the patients who were followed, on the other hand, showed consecutively negative cytology and pathology after cryosurgery. It is necessary for the more effective management of CIN with cryosurgery to perform endocervical curettage in every case, to select small lesion for treatment, and to use more powerful method of cryocauterization.

Adult↗
PubMed1981

Birth weight assessed by factor analysis.

To investigate the relevancy of birth weight, data on 300 term newborn infants were subjected to a reevaluation of 31 variables related to body measurements of both the mother and child and to the placenta. Factor analysis was introduced to analyze the data obtained. Each group was composed of multiple factor axes, of which factor structures were rather simple in Appropriate for Date (AFD) for approximating the practical images, compared to Heavy for Date (HFD) and Light for Date (LFD). In AFD, the birth weight was thought contributive by the limiting effect of the placenta, independently of the measurements of the mother. We found that the birth weight in itself seems to have a different meaning in each group, and it is difficult to readily categorize the findings on the table of equivalent parameters for labelling of the newborn.

Birth Weight↗
PubMed1980

[Histological grading of hydatidiform mole (author's transl)].

This study was performed to seek possibility of selecting the high risk group in the patients with hydatidiform mole at its delivery. The histologic specimens from 83 patients with hydatidiform mole were reviewed and classified by modified Hertig's grading. Lymphocyte count of peripheral blood was also studied as an immunological index. I. There were 36 Grade I cases, 16 Grade IIa, 23 Grade IIb, and 8 Grade III cases. Two subsequent destructive moles were found from the patients with Grade I, three from Grade IIb, and two from Grade III respectively. The incidence of developing subsequent destructive mole was 6% in Grade I, 8% in Grade II, and 25% in Grade III. II. There was no correlation between histological grading and patients age nor weeks in gestation. When the ratio of syncytiotrophoblast and cytotrophoblast was considered, most of Grade II or III cases were obtained from those in whom the cytotrophoblast prevailed over syncytiotrophoblast. III. The patients with lymphocyte less than 1500/mm3 in their peripheral blood were apt to take abnormal clinical course comparing to those with lymphocyte more than 1501/mm3. The more accurate prediction of clinical course was suggested by combination of histological grading and lymphocyte count.

Chorionic Gonadotropin↗